Breaking News

Variational AI, Merck Partner on Generative AI Project

Merck to evaluate Variational AI’s Enki generative AI platform to design novel and selective small molecules.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Variational AI, developer of the Enki generative AI platform for drug discovery, announced a project with Merck Research Laboratories supported by the CQDM Quantum Leap program. Merck will evaluate Enki’s ability to generate novel small molecules on targets of their choosing.   “We are pleased to announce Merck as an early-access user of our Enki Platform,” said Handol Kim, CEO, Variational AI. “We built and trained Enki as a foundation model that generates novel, selective, and synthesizable ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters